Data / Form D filings / STAQ Pharma, Inc.
STAQ Pharma, Inc.: Form D filings
STAQ Pharma, Inc., a pharmaceuticals company in Denver, CO, filed 11 Form D notices with the SEC between 2017 and 2024. The latest, on September 16, 2024, reports $11.4 million sold of a $30 million offering to 8 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 14135 E. 42ND AVE., UNIT 50, Denver, CO, 80239
- Phone
- (720) 961-2720
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Colorado
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1722397
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | New notice | $30,000,000 | $11,400,001 | $18,599,999 | 8 | Sep 4, 2024 | sec.gov |
| Jun 21, 2023 | Amendment | $20,000,000 | $10,121,691 | $9,878,309 | 17 | Apr 17, 2023 | sec.gov |
| Apr 28, 2023 | New notice | $20,000,000 | $8,011,665 | $11,988,335 | 10 | Apr 17, 2023 | sec.gov |
| Dec 23, 2021 | Amendment | $60,000,000 | $30,262,815 | $29,737,185 | 19 | Dec 21, 2020 | sec.gov |
| Mar 31, 2021 | Amendment | $9,000,000 | $9,000,000 | 23 | Apr 22, 2019 | sec.gov | |
| Jan 5, 2021 | New notice | $60,000,000 | $3,000,000 | $57,000,000 | 1 | Dec 21, 2020 | sec.gov |
| Apr 7, 2020 | Amendment | $9,000,000 | $7,785,650 | $1,214,350 | 20 | Apr 22, 2019 | sec.gov |
| Feb 25, 2020 | Amendment | $8,000,000 | $6,375,546 | $1,624,454 | 20 | Apr 22, 2019 | sec.gov |
| May 3, 2019 | New notice | $4,000,000 | $2,000,000 | $2,000,000 | 17 | Apr 22, 2019 | sec.gov |
| Apr 3, 2018 | New notice | $3,500,000 | $0 | $3,500,000 | 0 | Yet to occur | sec.gov |
| Nov 21, 2017 | New notice | $625,000 | $625,000 | 2 | Oct 31, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Scott M Hawig | Director | |
| Mark M Spiecker | Executive Officer, Director | |
| Carol M Lewis | Director | |
| Chet M Kaczor | Director | |
| Dan M Seff | Director | |
| Brad M Hauert | Director | |
| Joseph W Bagan | Executive Officer, Director | |
| Jeffrey L Hval | Executive Officer, Director | |
| Paul M Jenny | Director |
Every Form D from the week of Sep 16, 2024 · All recent filings in Colorado · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what STAQ Pharma, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.